"10.1371_journal.pone.0092597","plos one","2014-03-27T00:00:00Z","Hideki Tomioka; Hironori Nakagami; Akiko Tenma; Yoshimi Saito; Toshihiro Kaga; Toshihide Kanamori; Nao Tamura; Kazunori Tomono; Yasufumi Kaneda; Ryuichi Morishita","Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, Japan; AnGesMG, Inc., 7-7-15 Saito Bio-Incubator, Ibaraki, Osaka, Japan; Division of Vascular Medicine and Epigenetics, Osaka University United Graduate School of Child Development, 2-1 Yamada-oka, Suita, Osaka, Japan; Division of Gene Therapy Science, Osaka University Graduate School of Medicine, School of Child Development, 2-1 Yamada-oka, Suita, Osaka, Japan; Division of Infection Control and Prevention, Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, Japan","Conceived and designed the experiments: HN KT YK RM. Performed the experiments: HT HN AT YS T. Kanamori T. Kaga NT. Analyzed the data: HT AT T. Kanamori. Contributed reagents/materials/analysis tools: HT AT T. Kaga. Wrote the paper: HT HN.","Ryuichi Morishita is an Editorial Board Member of PLOS ONE. Ryuichi Morishita is a founder of AnGes MG, and a stockholder. AnGes MG has the following patent licenses of AG30/5C (PCT/JP2008/052020: Novel polypeptide and antibacterialagent comprising the same as active ingredient) and SR-0379 (PCT/JP2010/058838: Polypeptides and antibacterial or antiseptic use of same). Hideki Tomioka, AkikoTenma, Yoshimi Saito, Toshihiro Kaga, Toshihide Kanamori and Nao Tamura are employees of AnGes MG. Department of clinical gene therapy is financially supported by AnGes MG, Novartis, Shionogi, Boeringher, and Rohto. Division of VascularMedicine and Epigenetics is financially supported by Bayel. This study is partially supported by the fund of AnGes MG. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2014","03","Hideki Tomioka","HT",10,TRUE,4,5,3,2,TRUE,TRUE,FALSE,0,NA,FALSE
